1) There is a high need for additional phosphate binders given that most patients switch therapies each year due to safety, tolerability, and compliance issues.
2) KERX's Phase III trials could show that Zerenex has differentiated benefits in terms of safety, tolerability, fewer pills per day, and the possibility to treat anemia associated with dialysis and CKD patients.
3) The majority of phosphate binder sales come from markets outside the U.S., significantly tempering the impact of generic Renagel in the U.S.
Those that cost averaged and bought more shares upon each of those events are way ahead of the game and that again is why we call it a BUY & HOLD as opposed to a BUY & SOLD. I never sell anything for a loss but just keep buying to cost average until they get it right which is what seems to be about to happen. Why would you sell shares for a loss? You have a lot to learn. With each passing day, odds of approval and the buyout grow greater and greater. I took an insurance policy that guarantees I score when KERX scores. It is called a BUY & HOLD policy and most brokers offer them.